SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Nina Kreuzberger; Caroline Hirsch; Khai Li Chai; Vanessa Piechotta; Sarah J. Valk; Lise J. Estcourt; Susanne Salomon; Eve Tomlinson; Ina Monsef; Erica M. Wood; Cynthia So-Osman; David J. Roberts; Zoe McQuilten; Nicole Skoetz

doi:10.1002/14651858.CD013825

SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Nina Kreuzberger, Caroline Hirsch, Khai Li Chai, Vanessa Piechotta, Sarah J. Valk, Lise J. Estcourt^*, Susanne Salomon, Eve Tomlinson, Ina Monsef, Erica M. Wood, Cynthia So-Osman, David J. Roberts, Zoe McQuilten, Nicole Skoetz

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

50 Citations (Scopus)

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention, and to maintain the currency of the evidence, using a living systematic review approach. A secondary objective is to track newly developing SARS-CoV-2-targeting mAbs from first tests in humans onwards.

Original language	English
Article number	CD013825
Journal	The Cochrane database of systematic reviews
Volume	2021
Issue number	1
DOIs	https://doi.org/10.1002/14651858.CD013825
Publication status	Published - 15 Jan 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Access to Document

10.1002/14651858.CD013825

Cite this

Kreuzberger, N., Hirsch, C., Chai, K. L., Piechotta, V., Valk, S. J., Estcourt, L. J., Salomon, S., Tomlinson, E., Monsef, I., Wood, E. M., So-Osman, C., Roberts, D. J., McQuilten, Z., & Skoetz, N. (2021). SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. The Cochrane database of systematic reviews, 2021(1), Article CD013825. https://doi.org/10.1002/14651858.CD013825

@article{0b480b25ca754bc7aa838313a20d13d4,

title = "SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19",

abstract = "Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention, and to maintain the currency of the evidence, using a living systematic review approach. A secondary objective is to track newly developing SARS-CoV-2-targeting mAbs from first tests in humans onwards.",

author = "Nina Kreuzberger and Caroline Hirsch and Chai, {Khai Li} and Vanessa Piechotta and Valk, {Sarah J.} and Estcourt, {Lise J.} and Susanne Salomon and Eve Tomlinson and Ina Monsef and Wood, {Erica M.} and Cynthia So-Osman and Roberts, {David J.} and Zoe McQuilten and Nicole Skoetz",

note = "Publisher Copyright: Copyright {\textcopyright} 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.",

year = "2021",

month = jan,

day = "15",

doi = "10.1002/14651858.CD013825",

language = "English",

volume = "2021",

journal = "The Cochrane database of systematic reviews",

issn = "1465-1858",

publisher = "Cochrane Collaboration",

number = "1",

}

TY - JOUR

T1 - SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

AU - Kreuzberger, Nina

AU - Hirsch, Caroline

AU - Chai, Khai Li

AU - Piechotta, Vanessa

AU - Valk, Sarah J.

AU - Estcourt, Lise J.

AU - Salomon, Susanne

AU - Tomlinson, Eve

AU - Monsef, Ina

AU - Wood, Erica M.

AU - So-Osman, Cynthia

AU - Roberts, David J.

AU - McQuilten, Zoe

AU - Skoetz, Nicole

PY - 2021/1/15

Y1 - 2021/1/15

N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention, and to maintain the currency of the evidence, using a living systematic review approach. A secondary objective is to track newly developing SARS-CoV-2-targeting mAbs from first tests in humans onwards.

AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention, and to maintain the currency of the evidence, using a living systematic review approach. A secondary objective is to track newly developing SARS-CoV-2-targeting mAbs from first tests in humans onwards.

UR - http://www.scopus.com/inward/record.url?scp=85103049180&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD013825

DO - 10.1002/14651858.CD013825

M3 - Article

AN - SCOPUS:85103049180

SN - 1465-1858

VL - 2021

JO - The Cochrane database of systematic reviews

JF - The Cochrane database of systematic reviews

IS - 1

M1 - CD013825

ER -

SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this